Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVIR 
Atea Pharmaceuticals Inc (AVIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AVIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.22% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.18M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 0.24 | 52 Weeks Range 2.46 - 4.14 | Updated Date 09/14/2025 |
52 Weeks Range 2.46 - 4.14 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.16% | Return on Equity (TTM) -32.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -129284284 | Price to Sales(TTM) 1.9 |
Enterprise Value -129284284 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 79357600 | Shares Floating 60009388 |
Shares Outstanding 79357600 | Shares Floating 60009388 | ||
Percent Insiders 12.72 | Percent Institutions 71.91 |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address unmet medical needs for patients suffering from viral diseases. Founded in 2014, Atea has focused primarily on developing oral direct-acting antiviral agents for serious viral infections.
Core Business Areas
- Antiviral Drug Development: Focuses on researching and developing oral antiviral therapies for the treatment of severe viral infections, including COVID-19 and dengue.
Leadership and Structure
Jean-Pierre Sommadossi, PhD, is the founder and CEO. The organizational structure consists of research and development, clinical operations, regulatory affairs, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Bemnifosbuvir: An oral antiviral drug for the treatment of COVID-19. It targets the RNA polymerase of SARS-CoV-2. The clinical trials for this product did not yield satisfactory results, hence no current market share or revenue. Competitors include Pfizer (Paxlovid) and Merck (Molnupiravir).
Market Dynamics
Industry Overview
The antiviral therapeutics market is characterized by intense competition, driven by the ongoing need to address emerging and existing viral threats. Market size is substantial, influenced by factors like pandemic outbreaks, drug approvals, and government initiatives. The industry is highly regulated and research-intensive.
Positioning
Atea aims to carve out a niche in the oral antiviral market, specifically targeting severe viral infections, but is yet to be successful. Competitive advantages depend on demonstrating superior efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The global antiviral drugs market is estimated to be worth billions of dollars annually. Atea's positioning depends on the clinical success and commercial launch of their drug candidates.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Proprietary drug discovery platform
- Focus on oral antiviral therapies
Weaknesses
- Limited pipeline of approved products
- Dependence on single lead compound (Bemnifosbuvir) which failed in clinical trials
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new antiviral targets
- Government funding for antiviral research and development
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles and approval delays
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
Atea faces significant competition from larger pharmaceutical companies with established antiviral franchises and resources. Atea's success depends on demonstrating differentiated efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Atea's historical growth has been limited by a lack of approved products.
Future Projections: Future growth depends on successful clinical development and commercialization of antiviral drug candidates. Analyst projections are dependent on the outcome of their clinical trials.
Recent Initiatives: Focusing on pipeline refinement and exploring strategic partnerships.
Summary
Atea Pharmaceuticals is a development-stage company facing significant challenges due to failed clinical trials. While they possess a proprietary platform and an experienced team, their dependence on a single, now unsuccessful, lead compound has weakened their position. They need to secure partnerships and diversify their pipeline to ensure long-term survival. The financial data suggests a company that is struggling to get traction.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Atea Pharmaceuticals Inc. 10-K filings
- Analyst reports
- Company website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.